Cardiovascular Diseases Archives - MedicalAdvancesToday

5 min 0

Clinical Trials
Drug Development

A phase 1 clinical study showed a small molecule drug targeting lipoprotein (a) can reduce its level by 65%

Sandra Lin
August 29, 2023

This phase I clinical trial demonstrated that oral administration of Muvalaplin was effective in lowering lipoprotein(a) levels without serious side effects.

4 min 0

Nutrition & Diet
Research

Eating soybean-based food every day can reduce the risk of heart disease and diabetes

Justin Cheng
March 19, 2023

This systematic review and meta-analysis found that soybean intake is inversely associated with diabetes and cardiovascular disease.

Tag: Cardiovascular Diseases

A phase 1 clinical study showed a small molecule drug targeting lipoprotein (a) can reduce its level by 65%

Eating soybean-based food every day can reduce the risk of heart disease and diabetes

Healthy gut bacteria can help fight cancer elsewhere in the body

Only one mRNA vaccine shot can reduce HPV-related tumors, and the effect is better than DNA or recombinant protein vaccines

A 10-year follow-up study of nearly 13,000 people found that regular vitamin D supplementation reduces the risk of dementia by 40%

Researchers revealed the B cell mechanism of autoimmunity triggered by the clearance of susceptible macrophages in lymph nodes

A phase 1 clinical study showed a small molecule drug targeting lipoprotein (a) can reduce its level by 65%

For the first time in 20 years, FDA fully approved a new drug for Alzheimer’s disease

Scientists have discovered a novel target for Alzheimer’s Disease and the clinical results are astounding

Simufilam, an investigational oral drug for Alzheimer’s Disease, improved cognition in 47% of treated patients in a Phase 2 study

A phase 1 clinical study showed a small molecule drug targeting lipoprotein (a) can reduce its level by 65%

Scientists have discovered a novel target for Alzheimer’s Disease and the clinical results are astounding

Simufilam, an investigational oral drug for Alzheimer’s Disease, improved cognition in 47% of treated patients in a Phase 2 study